

British Association for the Study of the Liver

Annual Meeting 4-6 September 2013 QEII Conference Centre, London

DAY ONE – WEDNESDAY 4 SEPTEMBER

8.00 - 9.00	Early registration for Women in Hepatology meeting
9:00 – 10:00	Women in Hepatology meeting (Westminster Suite)
9:30 - 10:30	Registration and Coffee
10:30 – 12.24	HCC SYMPOSIUM Chair: Dr Phil Harrison
10:30 - 10:50	PART I - Is it all about to change? Molecular classification of HCC Dr Augusto Villanueva, Kings College London
10:50 - 11:10	Activation of signalling pathways in HCC Dr Helen Reeves, Northern Institute for Cancer Research
11:10 - 11:30	Prospects of therapeutic vaccination against cancer and chronic infections Prof Farzin Farzaneh, Kings College London
11:30 - 11:50	Integration of new drugs into the treatment pathway Prof Daniel Palmer, University of Liverpool
11:50 - 12:00	Discussion
12:00 - 12:24	PART II - HCC Free Papers
	A1 The interaction of human hepatocellular carcinoma with dendritic cells is able to induce a novel subset of CD8+ regulatory T-cells Ka-Kit Li et al, Centre for Liver Research and NIHR Biomedical Research Unit, University of Birmingham, Birmingham, UK
	A2 ImageStream Circulating Tumour Cell (CTC) detection in hepatocellular cancer (HCC) – preliminary pre-clinical and clinical data Laura Ogle et al, Northern Institute for Cancer Research, Newcastle University
12:30 - 13:30	Lunch and Satellite Symposium 1 – MSD (Mountbatten Room)
13:45 - 17:14	VIRAL SYMPOSIUM Chair: Prof Graham Foster













DAY ONE (Viral Symposium) ctd...

13:45 - 14:05	PART I - HCV - Are we there yet? Protease inhibitors, today and tomorrow - supporters for IFN? Prof Geoff Dusheiko, Royal Free London NHS Foundation Trust
14:05 - 14:20	NS5A inhibitors and cyclophilins - what will they bring? Prof Matthew Cramp, Plymouth Hospitals NHS Trust
14:20 - 14:35	NS5B inhibitors Dr Dan Forton, St George's Healthcare NHS Trust
14:35 - 15:05	Bringing it all together: IFN free therapy for all – what combinations will work and for who? Prof Nezam Afdhal, Beth Israel Deaconess Liver Centre
15:05 - 15:20	Discussion - When will these drugs be available?
15:20 - 15:50	Coffee
	PART II - Eradicating the virus - from the host and from society
15:50 - 16:05	Treat and clear the planet Dr Natasha Martin, University of Bristol
16:05 - 16:20	HCV in the cell - how does it avoid IFN? Prof John McLauchlan, University of Glasgow
16:20 - 16:35	Travelling around - cell to cell transfer of HCV Prof Jane McKeating, University of Birmingham
16:35 - 16:50	A vaccine coming soon or coming too late? Dr Ellie Barnes, Nuffield Dept of Medicine, University of Oxford
16:50 - 17:14	PART III - Viral Free Papers
	A3 Does previous Hepatitis B infection influence liver-related outcomes in patients with chronic hepatitis C Elizabeth Thomas et al, University of Glasgow
	Hepatitis C patients incur significantly greater healthcare costs, with or without cirrhosis - a nationwide analysis of hospital episode statistics Richard J Aspinall et al, Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, UK
17:30 - 18:30	Satellite Symposium 2 – Janssen (Westminster Suite)
19:00 - 22:00	President's Dinner (by invitation) Cinnamon Club













DAY TWO – THURSDAY 5 SEPTEMBER

7:15 - 9:00	Registration & Coffee
8:00 - 9:00	Satellite Symposium 3 – Gilead (Mountbatten Room)
9:10 - 11:00	FIBROSIS SYMPOSIUM Chair: Dr Ashley Brown
9:10 - 9:30	Fibrosis: challenges for the pathologist Dr Judy Wyatt, The Leeds Teaching Hospitals NHS Trust
9:30 - 9:50	Antifibrotic therapy: translation of basic science into clinical practice Dr Jonathan Fallowfield, University of Edinburgh
9:50 - 10:10	Selective targeting of fibrogenic NF-kappaB signalling in liver fibrosis therapy Dr Fiona Oakley, The Leeds Hospital NHS Trust
10:10 - 10:30	Coagulation and fibrosis Prof Mark Thursz, Imperial College
10:30 - 11:00	Ralph Wright Lecture Fibrosis and repair Prof Stuart Forbes, University of Edinburgh
11:00 - 11:30	Coffee
11:30 - 12:00	Sheila Sherlock Prize Lecture Chair: Prof Graham Foster The role of CLEVER-1 in lymphocyte recruitment- a potential therapeutic target in inflammatory liver disease Dr Shishir Shetty MRCP PhD, Wellcome Intermediate Clinical Fellow, University of Birmingham
12:00 - 13:00	FREE PAPERS Chair: Dr Mark Hudson
	Award Presentation by Professor Roger Williams Winner of the 'Foundation for Liver Research Award for Basic Science': Identification and characterization of a novel cancer cell survival effector in hepatocellular carcinoma Salvatore Papa et al, Cell Signalling and Cancer Laboratory, Institute of Hepatology London, Foundation for Liver Research, UK
	A6 Everolimus-based immunosuppression provides superior renal function and comparable efficacy versus standard tacrolimus in de novo liver transplant recipients: 24-month results of a randomised controlled trial A MacGilchrist et al, Royal Infirmary of Edinburgh, Edinburgh, Scotland
	A7 Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease Stuart McPherson et al, Freeman Hospital, Newcastle upon Tyne, UK
	A8 Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon therapy in Chronic Hepatitis B Upkar S. Gill et al, Hepatology Unit, Centre for Digestive Diseases, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom













DAY TWO (Free Papers) ctd...

A9

Jason Coombes et al, The Institute of Hepatology, Foundation for Liver Research, London 13:00 - 14:00 **Lunch and Directed Poster Viewing** 14:00 - 16:00 TRANSPLANTATION SYMPOSIUM Co-chairs: Prof Derek Manas and Prof John O'Grady 14:00 - 14:30 Williams-Calne Lecture Liver Failure and Liver Transplantation for "Non Alcoholic Steatohepatitis" Prof M. Charlton, USA 14:30 - 14:45 How best to assess the high-risk recipient Dr Will Bernal, King's College Hospital NHS Foundation Trust 14:45 - 15:05 'The day I reached my limit' Dr Mark Hudson, The Newcastle Upon Tyne Hospitals NHS Foundation Trust Mr John Isaac, University Hospitals Birmingham NHS Foundation Trust HCV: Managing post transplant drug interactions in 2013 15:05 - 15:35 Dr Audrey Coilly, Paris 15:35 - 16:00 Debate: The house believes that too much resource has been allocated to transplanting recipients with HCC For: Prof John O'Grady / Against: Dr Alex Gimson 16:00 - 16:30 Coffee 16:30 - 17:30 **END OF LIFE SYMPOSIUM Chair: Amanda Clements** 16:30 - 16:40 Case Study Amanda Clements, Plymouth Hospitals NHS Trust 16:40 - 17:10 Getting it right: improving end of life care for people with liver disease Dr Stuart Kendrick, Institute of Cellular Medicine, Newcsatle-upon-Tyne 17:10 - 17:30 Innovative approaches in caring for patients with end stage liver disease Mark Holmes, Nottingham University Hospitals NHS Trust 17:30 - 18:00 A SUMMARY OF NATIONAL STUDIES Prof Will Irving, University of Nottingham; Prof Graham Foster, QMUL 18:00 - 19:00 **Directed Poster Viewing** Refreshments will be served 19:30 - 23:00 **Annual Dinner**

nonalcoholic steatohepatitis

Osteopontin enhances liver progenitor response during progressive













DAY THREE - FRIDAY 6 SEPTEMBER

9:10 - 10:34

7:15 - 9:00**Registration & Coffee** 8:00 - 9:00 Satellite Symposium 4 – Norgine (Westminster Suite)

PART I - FREE PAPERS

Co-Chair: Profs Matthew Cramp & Geoff Dusheiko

- A10 Non-invasive biomarkers unearth undiagnosed cirrhosis in the community David J Harman et al, NIHR Nottingham Digestive Diseases Biomedical Research Unit
- A11 A novel multi-genotypic "naturally" infectious system to study hepatitis C virus (HCV) infection in vitro Antonio Riva et al, The Institute of Hepatology, Foundation for Liver Research
- A12 Functional, anthropometric and prognostic associations of muscle wasting assessed by Computed-Tomography in patients with cirrhosis Ziva Mrevlje et al, Institute of Liver Studies, Kings College Hospital
- A13 Gene expression analysis of recipient NK cells after Liver Transplantation demonstrates downregulation of STAT4 Khaleel M Jamil et al, Imperial College London
- A14 Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults Upkar S. Gill et al, Hepatology Unit, Centre for Digestive Diseases, Blizard Institute, Barts and The London SMD, QMUL, London, United Kingdom
- A15 Generation of hepatocytes from Arthrogryposis-Renal dysfunction-Cholestasis (ARC) syndrome patient-derived induced Pluripotent Stem Cells Maëlle Lorvellec et al, School of Immunity & Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
- A16 Expression of interferon-stimulated genes (IGS) in the liver – role for predicting response to antiviral therapy in chronic hepatitis B infection? Ivana Carey et al, King's College Hospital NHS Foundation Trust

Award to winning poster presentation

10:35 - 11:00 Coffee 11:00 - 12:00 **PART II - An Update on Autoimmune Liver Disorders** Chair: Dr Graeme Alexander 11:00 - 11:20 Prof David Jones, University of Newcastle 11:20 - 11:40 **PSC** Dr Roger Chapman, Oxford University Hospitals NHS Trust













DAY THREE ctd...

11:40 - 12:00	Autoimmune Hepatitis Prof Ansgar Lohse, University Hamburg
12:00 - 12:50	Annual Business Meeting and Review (Members Only)
13:00 - 14:00	Lunch and Satellite Symposium 5 – BMS (Westminster Suite)
14:10 - 16:00	ALCOHOL SYMPOSIUM Co-Chairs: Dr Bill Griffiths, Dr Nick Sheron Also joined by Dr Michael Glynn, Barts Health NHS Trust & National Clinical Director for GI and Liver Diseases at the National Commissioning Board
14:00 - 14:30	BLT Lecture Health First: A comprehensive approach to addressing alcohol harm Prof Linda Bauld, University of Stirling
14:30 - 15:00	Measuring the Units: A review of patients who died with alcohol-related liver disease Dr Neil Smith, Deputy Chief Executive, NCEPOD
15:00 - 15:20	Alcohol care teams and collaborative liver and psychiatry care Dr Kieran Moriarty, Bolton NHS Trust
15:20 - 15:40	Moving the national alcohol agenda forwards Dr Nick Sheron, Southampton University
15:40 - 16:00	Open forum debate













SPONSOR LIST

Satellite Sponsors

Bristol-Myers Squibb Pharmaceuticals Ltd Gilead Janssen Merck Sharp & Dohme Ltd Norgine Pharmaceuticals Ltd

Major Sponsors

Janssen Therapeutics

Key Sponsors

Boehringer-Ingelheim Ltd

Sponsors

AbbVie Roche Products Ltd

Associate Sponsors

Astellas Pharma UK Ltd Echosens Lundbeck Ltd Sequana Medical AG

Exhibitors

British Liver Trust Children's Liver Disease Foundation











